Ursodeoxycholic acid and severe COVID-19 outcomes in a cohort study using the OpenSAFELY platform

Ursodeoxycholic acid and severe COVID-19 outcomes in a cohort study using the OpenSAFELY platform

Abstract Background Biological evidence suggests ursodeoxycholic acid (UDCA)—a common treatment of cholestatic liver disease—may prevent severe COVID-19 outcomes. We aimed to compare the hazard of COVID-19 hospitalisation or death between UDCA users versus non-users in a population with primary bili...

Full description

Bibliographic Details
Main Authors: Ruth E. Costello, Karen M. J. Waller, Rachel Smith, George F. Mells, Angel Y. S. Wong, Anna Schultze, Viyaasan Mahalingasivam, Emily Herrett, Bang Zheng, Liang-Yu Lin, Brian MacKenna, Amir Mehrkar, Sebastian C. J. Bacon, Ben Goldacre, Laurie A. Tomlinson, John Tazare, Christopher T. Rentsch, the OpenSAFELY collaborative, the LH&W NCS (or CONVALESCENCE) Collaborative
Format: Article
Language:English
Published: Nature Portfolio 2024-11-01
Series:Communications Medicine
Online Access:https://doi.org/10.1038/s43856-024-00664-y

Internet

https://doi.org/10.1038/s43856-024-00664-y

Similar Items